Latest Breaking News On - Naoya miura - Page 1 : comparemela.com

(Reuters) -Daiichi Sankyo said the U.S. health regulator has approved its drug for treating newly diagnosed patients suffering from an aggressive type of blood cancer, pitting the treatment against those from rivals Novartis and Astellas. The drug, which is already approved in Japan has faced a long path to the U.S. market, with the Food and Drug Administration (FDA) declining to approve it in 2019 in a different set of acute myeloid leukemia (AML) patients and then extending its review by three

Daiichi sankyoNovarti rydaptNaoya miuraShounak dasguptaKen kellerSriparna royShailesh kuberDrug administration